Next-Generation Sequencing for Lymphomas: Perfecting a Pipeline for Personalized Pathobiologic and Prognostic Predictions.

This commentary highlights the article by Hung et al that details the design and implementation of a 32-gene next-generation sequencing panel for lymphomas and compares hybrid-capture with amplicon-based next-generation sequencing approaches.

[1]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[2]  Michelle N Wurst,et al.  Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. , 2017, The Journal of molecular diagnostics : JMD.

[3]  Raul Rabadan,et al.  Genetics of follicular lymphoma transformation. , 2014, Cell reports.

[4]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[5]  J. Datta,et al.  Comparison of custom capture for targeted next-generation DNA sequencing. , 2015, The Journal of molecular diagnostics : JMD.

[6]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[8]  M. Calaminici,et al.  Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.

[9]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[10]  B. Nadel,et al.  Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies , 2017, Journal of internal medicine.

[11]  Lackner,et al.  The Role of Next‐Generation Sequencing in Enabling Personalized Oncology Therapy , 2016, Clinical and translational science.

[12]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[13]  Marina N Nikiforova,et al.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[14]  J. Aster,et al.  Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. , 2016, The Journal of molecular diagnostics : JMD.

[15]  Eric Samorodnitsky,et al.  Evaluation of Hybridization Capture Versus Amplicon‐Based Methods for Whole‐Exome Sequencing , 2015, Human mutation.

[16]  J. Cerhan,et al.  2016 US lymphoid malignancy statistics by World Health Organization subtypes , 2016, CA: a cancer journal for clinicians.

[17]  A. López-Guillermo,et al.  Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. , 2015, Blood.

[18]  R. Gascoyne,et al.  Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management. , 2018, The Journal of molecular diagnostics : JMD.